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Abstract
Widespread use of pancreatic islet transplantation for treatment of type 1 diabetes (T1D) is currently
limited by requirements for long-term immunosuppression, limited donor supply, and poor long-term
engraftment and function. Upon isolation from their native microenvironment, islets undergo rapid
apoptosis, which is further exacerbated by poor oxygen and nutrient supply following infusion into the
portal vein. Identifying alternative strategies to restore critical microenvironmental cues, while maximizing
islet health and function, is needed to advance this cellular therapy. We hypothesized that biophysical
properties provided through type I oligomeric collagen macroencapsulation are important considerations
when designing strategies to improve islet survival, phenotype, and function. Mouse islets were
encapsulated at various Oligomer concentrations (0.5–3.0 mg/ml) or suspended in media and cultured for
14 days, after which viability, protein expression, and function were assessed. Oligomer-encapsulated islets
showed a density-dependent improvement in in vitro viability, cytoarchitecture, and insulin secretion, with
3 mg/ml yielding values comparable to freshly isolated islets. For transplantation into streptozotocin-
induced diabetic mice, 500 islets were mixed in Oligomer and injected subcutaneously, where rapid in situ
macroencapsulation occurred, or injected with saline. Mice treated with Oligomer-encapsulated islets
exhibited rapid (within 24 h) diabetes reversal and maintenance of normoglycemia for 14
(immunocompromised), 90 (syngeneic), and 40 days (allogeneic). Histological analysis showed Oligomer-
islet engraftment with maintenance of islet cytoarchitecture, revascularization, and no foreign body
response. Oligomer-islet macroencapsulation may provide a useful strategy for prolonging the health and
function of cultured islets and has potential as a subcutaneous injectable islet transplantation strategy for
treatment of T1D.
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INTRODUCTION
Type 1 diabetes (T1D) is a debilitating and burdensome public health problem affecting an estimated 1.25
million men, women, and children in the U.S. alone (10). The current standard of care is exogenous insulin
with whole pancreas transplantation exercised only in the most difficult-to-treat cases in which there exists
severe hypoglycemia unawareness. Although insulin therapy is life-saving, it provides inferior control
relative to functional islet cells and does not eliminate chronic complications (i.e., cardiovascular disease,
kidney failure, retinopathy, and neuropathy) that contribute to a large portion of medical costs and loss of
quality of life (41). Even with a strict insulin regimen, T1D patients still experience dangerously high or
low blood glucose levels that can potentially be life threatening. In fact, less than one-third of people with
T1D in the U.S. consistently achieve target blood glucose levels (25).
Although pancreatic islet transplantation is an attractive therapeutic alternative for T1D patients, this
approach remains classified as experimental in the U.S. since long-term safety and efficacy have yet to be
achieved (7). At present, clinical islet transplantation involves image-guided infusion of a large number of
islets [on average 800,000 islet equivalents (IE) over 2 infusions derived from 4–6 patients] into the portal
vein where they become lodged (42). Early results associated with the Edmonton procedure highlighted the
potential of this cellular therapy (58). More recently, a multicenter Phase III clinical allogeneic islet
transplantation trial was completed, providing favorable data for use in a Biologics License Agreement
submission to the U.S Food and Drug Administration (20). Despite these successes, a number of persistent
obstacles preclude it from gaining more widespread use. Specifically, there exists a limited supply of
quality-controlled donor islets for transplant, and the requirement for long-term immunosuppression has
significant side effects (59). Most importantly, the longevity and function of transplanted islets must be
improved for patients to achieve long-term insulin independence. Poor islet engraftment and performance
have been attributed to loss of critical microenvironmental cues from surrounding extracellular matrix
(ECM) and vasculature as a result of islet isolation as well as the rapid blood-mediated inflammatory
reaction following islet transplantation (17, 52).
Numerous macro- and microencapsulation strategies, involving natural and synthetic biomaterials, have
been developed in an attempt to create a protective microenvironment and physical barrier that prevents
detection and accessibility of transplanted islets by the immune system. Unfortunately, these physical
barriers also hinder islet engraftment and associated revascularization and reinnervation, which are known
to promote islet health and function. Fibrotic capsule formation, largely owing to poor material
biocompatibility, further hinders essential mass transport. Incremental improvement has been achieved by
1) transplanting encapsulated islets into highly vascularized alternative sites (e.g., omentum) (5), 2)
providing supplemental oxygenation strategies (37), and 3) codelivering angiogenic factors, anti-
inflammatory factors, and accessory cells (69, 71); however, reliable and reproducible long-term survival
and function of encapsulated islets have yet to be achieved.
Although less understood mechanistically, the interface between islet cells and their extracellular
microenvironment provides essential biochemical and biophysical cues that guide not only islet
morphogenesis during fetal development but also postnatal homeostatic islet function (26, 27, 65). In vivo,
these islet microorgans interact with various ECM components, including fibrillar type I collagen, which is
present within and around islets as well as within perivascular capillaries, although species- and age-
dependent differences exist (14, 64). Engagement of specific collagen motifs has been shown to promote
islet cell survival, differentiation, and β cell function by triggering downstream signaling pathways, in part
through integrin and discoindin receptors (53, 56). Additional reports indicate that embedment within
three-dimensional (3D) collagen matrixes, in contrast to 2D surface contact, helps to sustain the necessary
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Mouse islets.
Oligomeric collagen encapsulation of mouse islets for in vitro culture.
cell polarity and organization for prolonged islet function (12, 36, 43). Clearly, collagen biophysical
properties, including matrix architecture, stiffness, and resistance to proteolytic degradation, are important
for guiding proliferation, differentiation, and morphogenesis of various embedded cell types; however, little
is known regarding how these parameters influence multicellular functional units, such as islets.
In the present study, we hypothesized that biophysical properties of a rheologically tunable type I
oligomeric collagen (Oligomer) were important determinants of islet viability, cytoarchitecture, and
function following macroencapsulation in vitro and in vivo. Unlike monomeric (atelocollagen or
telocollagen) collagen formulations, which have been previously employed for islet encapsulation,
Oligomers retain natural intermolecular crosslinks, which support rapid and robust fibril self-assembly
upon neutralization, yielding highly interconnected, D-banded, fibrillar scaffolds (4, 6, 32, 73). When
compared with monomeric collagens prepared at the same concentration, Oligomer matrices exhibit
improved mechanical stability (stiffness and strength) and resistance to proteolytic degradation (6, 32).
Initial in vitro studies applied confocal microscopy, immunostaining, and glucose-stimulated insulin
secretion (GSIS) testing to monitor the dependence of islet viability, cytoarchitecture, collagen remodeling,
and function following macroencapsulation at various Oligomer concentrations (fibril densities). Oligomer
solutions were then utilized for subcutaneous injection and in situ macroencapsulation of islets within
streptozotocin-induced diabetic mice. The subcutaneous space was selected as an alternative transplant site
to the portal vein since it offers easy accessibility via injection, potential for monitoring and imaging, as
well as retrievability, if necessary, of the transplanted islets. Specifically, short-term (14-day) studies in
immunocompromised NOD/SCID mice were used to characterize biocompatibility of Oligomer material
and islet engraftment. Follow-up studies evaluated long-term (90-day) survival and function of Oligomer-
encapsulated syngeneic islets following subcutaneous delivery in immune competent C57BL/6J mice.
Finally, a pilot allogeneic study (60-day) was performed to determine the immunoprotective capacity of
Oligomer-encapsulated islets.
MATERIALS AND METHODS
Mouse pancreatic islets were isolated from 8- to 14-wk old C57BL/6J or CD1 mice (Jackson
Laboratory, Bar Harbor, ME) as described (66). Islet isolations were approved by the Indiana University
Institutional Animal Care and Use Committee using AAALAC guidelines. Isolated islets were incubated in
RPMI 1640 medium supplemented with 10% fetal bovine serum (HyClone, ThermoFisher Scientific,
Waltham, MA), 100 U/ml penicillin, and 100 µg/ml streptomycin (Sigma Aldrich, St. Louis, MO) in a
humidified environment of 5% CO  in air at 37°C before experimental use the next day.
Type I oligomeric collagen
(Oligomer) was acid-solubilized from the dermis of market-weight pigs and lyophilized for storage as
described previously (32). The Oligomer formulation was standardized on the basis of molecular
composition as well as polymerization capacity according to the voluntary consensus standard ASTM
F3089–14 (2a). Here the polymerization capacity is defined by the matrix shear storage modulus, G′ (in
Pa), as a function of oligomer concentration in the polymerization reaction.
Oligomer polymerization kinetics were measured using an AR2000 rheometer (TA Instruments, New
Castle, DE) equipped with a stainless steel, 40-mm-diameter parallel plate geometry. Upon lowering the
geometry, the Peltier plate was maintained at 4°C for 2 min and then increased to 37°C for 10 min to
induce collagen polymerization. Time-dependent changes in shear storage modulus (G′) were measured at
1% controlled oscillatory strain. Polymerization half-time was defined as the time required for G′ to reach
half-maximum value (n = 4–5 for each formulation).
Oligomer was diluted with 0.01 N HCl and neutralized to final concentrations of 0.5, 1.5, or 3.0 mg/ml,
corresponding to polymerized matrices with G′ values of 40, 200, and 1,000 Pa, respectively. Mouse islets
2
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Assessment of mouse islet viability, cytoarchitecture, and function following in vitro culture.
Subcutaneous islet transplantation in diabetic mice.
were suspended in the neutralized Oligomer solutions, aliquoted into 96-well plates (30 islets/100 µl;
Cellvis, Sunnyvale, CA), and allowed to polymerize at 37°C. Oligomer solutions (in the presence or
absence of cells) were maintained on ice (4°C) before warming to 37°C to induce rapid polymerization.
Immediately following polymerization, culture medium was added, and the Oligomer-islet constructs were
cultured for up to 14 days with medium changes made daily. For comparison purposes, mouse islets were
also cultured in a conventional suspension format.
Islets
cultured in suspension or embedded in Oligomer were treated with calcein AM and propidium iodide
(Molecular Probes, Eugene, OR) for live-dead determinations. Images were collected using laser scanning
confocal microscopy on an Olympus IX81 inverted microscope adapted with Olympus Fluoview FV1000
(Olympus, Tokyo, Japan). Image stacks of 40- to 100-µm thickness with a 3-µm step size were obtained
using a 20× air objective, and z-projections were created using Imaris software (Bitplane, Concord, MA).
Immunofluorescence was used to qualitatively assess islet cytoarchitecture and protein expression. Islets
cultured in suspension or embedded in Oligomer were fixed in 3% paraformaldehyde (Mallinckrodt,
Derbyshire, UK), permeabilized with 0.1% Triton X-100 (Sigma Aldrich), and blocked with 1% bovine
serum albumin (Jackson ImmunoResearch, West Grove, PA). Samples then were treated overnight at 4°C
with primary guinea pig anti-insulin (PA1–26938, Invitrogen, Carlsbad, CA) and rabbit anti-glucagon
antibodies (ab10988, Abcam, Cambridge, MA). Samples were rinsed and then treated with secondary
antibodies (A11073, goat anti-guinea pig Alexa Fluor 488 conjugate and A11035, goat anti-rabbit Alexa
Fluor 546 conjugate, Life Technologies, Carlsbad, CA) overnight at 4°C. After rinsing, samples were
treated with DRAQ5 (Cell Signaling Technologies, Danvers, MA) to stain nuclei.
Quantitative assessment of islet function was performed via GSIS testing. Islets cultured in suspension or
encapsulated in Oligomer were prepared within 24-well Transwell culture inserts (Corning, Kennebunk,
ME) for up to 14 days. Basal insulin secretion was stimulated by incubating the samples for 1 h with 2.8
mM glucose in Krebs Ringer buffer (0.1% BSA, 25 mM HEPES, 115 mM NaCl, 24 mM NaHCO , 5 mM
KCl, 1 mM MgCl ·6H O, 2.5 mM CaCl ·2H O). Following basal secretion, samples underwent static
incubation for 1 h each, with low (2.8 mM) followed by high (28 mM) glucose concentrations in Krebs
Ringer buffer. Insulin secretion was measured using a STELLUX insulin enzyme-linked immunosorbent
assay (ELISA) kit (Alpco, Salem, NH). Stimulation indexes (SI), which represent the ratio of insulin
secreted with high glucose over insulin secreted with low glucose, were calculated and normalized to
values obtained for freshly isolated (day 0) islets.
Mouse islet transplantation procedures were
approved by the Indiana University Institutional Animal Care and Use Committee using AALAC
guidelines. Male 8-wk to 14-wk old NOD.CB17-Prkdc /J (immunocompromised model; Jackson
Laboratories, Bar Harbor, ME) or C57BL/6J (syngeneic and allogeneic models) recipient mice were
injected with low-dose streptozotocin (55 mg/kg) for 5 days to chemically induce diabetes before islet
transplantation (39). C57BL/6J (immunocompromised and syngeneic models) or CD1 (allogeneic model)
islets were mixed with neutralized Oligomer solutions. Oligomer-islet suspensions were then injected
subcutaneously through small-bore needles (26 gauge) into diabetic mice. Each mouse received 2
injections, one positioned laterally on each side of the back, with 250 islets/500 µl Oligomer per site for a
total of 500 islets/mouse. Additional mice received 2 injections of islets suspended in saline (islets only
control; 250 islets/500 µl saline per site) or neutralized Oligomer solution (Oligomer only control; 500 µl
Oligomer/site) for comparison. For the immunocompromised model, experimental groups included 1.5
mg/ml Oligomer (n = 3), 2.2 mg/ml Oligomer (n = 3), 3.0 mg/ml Oligomer (n = 3), Oligomer only control
(n = 3), and islets-only control (n = 4). For the syngeneic model, 3.0 mg/ml Oligomer (n = 3) and islets
only (n = 3) were used. For the allogeneic model, 3.0 mg/ml Oligomer (n = 3) and 4.2 mg/ml Oligomer (n
3
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Intraperitoneal glucose tolerance test.
In vivo histology and immunofluorescence.
Oligomer fibril architecture affects viability, cytoarchitecture, and function of cultured islets.
Subcutaneous injection and in situ oligomer macroencapsulation of islets supports rapid
engraftment and reversal of diabetes in immunocompromised mice.
= 5) were used. Nonfasting blood glucose was measured 3 times per week after transplantation. Diabetes
was classified as two consecutive blood glucose levels above 300 mg/dl. Based on preferences and
standards established in the literature, a blood glucose level of 250 mg/dl was selected as the “diabetic
threshold” (31, 34). At the end of the study, the pancreas was removed and histopathological analysis
performed to confirm destruction of endogenous islets.
Intraperitoneal glucose tolerance tests (GTT) were performed at
specified times following subcutaneous transplantation to assess islet responsiveness to glucose challenges.
Mice were fasted overnight, and then injected intraperitoneally with 2 g/kg of 20% glucose. Blood glucose
levels were measured at baseline before injection (time 0) and 15, 30, 60, 90, and 120 min following
glucose injection.
Injection sites and surrounding tissues were removed at
specified times and placed in 10% formalin before paraffin embedding and sectioning. Sections were
stained with hematoxylin and eosin (H&E) and Masson’s trichrome (MTC). For immunofluorescence,
sections were deparaffinized, rehydrated, and stained with primary guinea pig anti-insulin (A0564, Dako,
Santa Clara, CA) and rabbit anti-glucagon (sc-13091, Santa Cruz Biotechnology, Dallas, TX) at 1:500
dilutions. Sections were then treated with secondary Alexa Fluor 488 goat anti-guinea pig (A11073, Life
Technologies) and Alexa Fluor 568 goat anti-rabbit (A11036, Life Technologies) at 1:50 and 1:200
dilutions, respectively. For identification of vascular endothelium, sections were stained with primary
mouse anti-CD31/PECAM-1 (BBA7, R&D Systems, Minneapolis, MN) then treated with secondary Alexa
Fluor 546 donkey anti-mouse (A10036, Life Technologies). Nuclei were counterstained with DAPI.
RESULTS
It has
been suggested that loss of critical microenvironmental cues upon islet isolation and culture decreases
component cell viability and function, thereby compromising islet health and transplant outcomes (59, 65).
To better define how biophysical properties of fibrillar type I collagen affects overall islet health and
function, isolated C57BL6/J mouse islets were macroencapsulated in Oligomer ranging from 0.5 to 3.0
mg/ml and cultured for 14 days. Previous reports show that increasing Oligomer concentration yields
matrices of increased stiffness (G′) as a result of increased fibril density (32). Freshly isolated islets and
islets maintained in conventional suspension culture served as positive and negative controls, respectively.
As expected, suspension islets showed a progressive loss of viability over the 14-day culture period (
Fig. 1A), contributing to altered morphology (Fig. 2A) and significant loss of function (68.2 ± 2.8%), as
measured by GSIS (Fig. 2B, P < 0.05). By contrast, Oligomer-encapsulated islets displayed improved
viability (Fig. 1, B–E) and morphology (Fig. 2A), which was dependent upon fibril density. Islet cells
actively adhered and exerted contractile forces on the surrounding collagen-fibril matrix, which was
evident both macroscopically (construct contraction) and microscopically (islet-collagen interactions).
Although the majority (≥66%) of Oligomer-0.5 constructs contracted, hindering further analysis, all
Oligomer-1.5 and Oligomer-3.0 constructs retained their volume, displaying minimal to no islet cell death (
Fig. 1, B and C) and progressively less local fibril reorganization with increased concentration (
Fig. 1, D and E). Immunostaining confirmed that encapsulated islets stained positively for insulin and
glucagon, indicating maintenance of cytoarchitecture and phenotype (Fig. 2A). Additionally, islets
maintained in Oligomer-1.5 and Oligomer-3.0 over the 14-day culture period retained glucose-sensitive
insulin release, with normalized SI values of 73.2 ± 3.0% and 98.9 ± 5.6%, respectively, when compared
with freshly isolated islets (Fig. 2B).
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Long-term reversal of diabetes following delivery of oligomer-encapsulated syngeneic islets.
Since Oligomer-islet macroencapsulation prolonged islet viability and function in vitro, Oligomer
formulations were evaluated for their ability to support subcutaneous delivery and engraftment of islets in
chemically induced diabetic mice. This minimally invasive transplantation strategy involved mixing islets
within Oligomer solutions followed by subcutaneous injection into streptozotocin-induced diabetic mice as
shown in Fig. 3A. Each mouse received 2 injections, one on each side of its back. All mice receiving
transplanted islets were injected with a total of 500 islets (250 islets/500 µl per site). Immediately following
injection, the Oligomer-islet suspension self-assembled in situ, forming a stable and continuous collagen-
fibril matrix that encapsulated and protected resident islets between the panniculus carnosus muscle and
skeletal muscle fascial layer (Fig. 4). The polymerization half-time for Oligomer at body temperature
(37°C) was 20.26 ± 0.12 s, 16.28 ± 0.03 s, 16.35 ± 0.11 s, as measured rheometrically for Oligomer −1.5,
−2.2, and −3.0 mg/ml, respectively.
Initial studies involved transplantation of C57BL/6J mouse islets into NOD.CB17-Prkdc /J mice, which
exhibit acute inflammation but no T- and B cell mediated immune reactions. The goal was to assess short-
term (14-day) morphology and function of transplanted islets as well as Oligomer biocompatibility and
tissue response. For these studies, Oligomer solutions at concentrations of 1.5, 2.2, and 3.0 mg/ml (n = 3
for each group), which correspond roughly to Oligomer stiffness values 200, 500, and 1,000 Pa based upon
standardized polymerization capacity, were employed. Based on in vitro results, these groups were selected
to define how Oligomer concentration (collagen fibril density) modulated islet survival, phenotype, and
transport properties associated with their glucose-sensitive insulin release. Prior to islet transplant, mean
blood glucose values were 533 ± 72 mg/dl, which was the highest among the mouse strains used for this
work.
As shown in Fig. 3B, islets + Oligomer-3.0 provided the most reproducible reversal of diabetes in all
animals (consistent maintenance of blood glucose values below the diabetic threshold) and highly regulated
blood glucose levels (small SD bars). Additionally, nonfasting blood glucose decreased below the diabetic
level within 24 h and remained below the diabetic level for the entire 14-day study period (Fig. 3B). In
contrast, both islet only and Oligomer only control groups remained hyperglycemic, above the diabetic
level, for the entire 14-day study (Fig. 3B). As shown in Fig. 4, the most uniform encapsulation of
individual islets was achieved with Oligomer-3.0, with islets maintaining their normal morphology with
evidence of functional revascularization. Islet aggregates were noted within Oligomer-1.5 and -2.2,
suggestive of insufficient fibril density for encapsulation and/or inadequate mixing. Immunostaining of
Oligomer-islet constructs confirmed a multicellular islet cytoarchitecture with both insulin- and glucagon-
producing cells (Fig. 4, D, H, L, and O). Surrounding the islets, the self-assembled Oligomer appeared as
normal collagenous connective tissue, which increased in density with concentration. A density-dependent
fibroblast infiltration was observed with no evidence of inflammation or foreign body response, which is
consistent with previous in vivo studies (8, 76). The fibrillar Oligomer was highly stable and well-
integrated within the subcutaneous space for all islet + Oligomer and Oligomer only (n = 3) groups (data
not shown). In contrast, for the islet only group (n = 4), large granulomatous regions were observed with no
identifiable islets (Fig. 4, M–O). Such findings are consistent with previous reports that suggest that the
subcutaneous space is an inhospitable microenvironment for transplantation of islets alone (30, 46).
To
assess long-term survival and function of Oligomer-encapsulated islets following subcutaneous delivery,
C57BL/6J mouse islets were injected into C57BL/6J mice (syngeneic transplant). For this study, only
Oligomer-3.0 was used. Mean blood glucose levels on the day of transplantation were 344 ± 27 mg/dl.
Once transplanted, Oligomer-encapsulated islets showed rapid engraftment, again reversing diabetes within
24 h of transplantation in all recipients (Fig. 5A). Additionally, all mice remained below the diabetic level
throughout the 90-day study period with small standard deviations, indicative of tight regulation of blood
glucose. In contrast, mice transplanted with islets only remained diabetic with blood glucose values over
scid
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Pilot studies show reversal of diabetes with immune modulation following in situ oligomer
encapsulation of allogeneic islets.
400 mg/dl (Fig. 5A). Intraperitoneal glucose tolerance testing (GTT) was performed on day 15 (
Fig. 5, B and C) and 90 (Fig. 5, D and E) to further assess glucose responsiveness of transplanted islets.
Interestingly, mice transplanted with Oligomer-encapsulated islets achieved normoglycemia 120 min post-
glucose injection while blood glucose in islet only mice remained elevated above basal levels (
Fig. 5, B and D). Analysis of area under the curve (AUC) indicated that values for Oligomer-islet mice
were significantly lower than those for islet only mice at both 15- and 90-day time points (P < 0.05;
Fig. 5, C and E). Histolopathologic and immunostaining analyses showed Oligomer persistence at 90 days
with integration into the surrounding subcutaneous tissue compartment and no evidence of chronic
inflammatory or foreign body response (Fig. 6A). Within Oligomer, islets maintained their rounded,
multicellular architecture insulin- and glucagon-positive cells (Fig. 6, A–C) and nearby patent vasculature (
Fig. 6B) and CD-31 positive cells (Fig. 6, D and E). As expected, islet-only explants showed a robust
foreign-body response indicative of graft failure (Fig. 6, F and G).
To assess function and immunoprotection of Oligomer-encapsulated islets following subcutaneous delivery,
pilot allogeneic transplantation studies were performed, where CD1 mouse islets were injected into diabetic
C57BL/6J mice. Prior to islet transplant, mean blood glucose values were 378 ± 74 mg/dl. When
Oligomer-3.0 was applied, blood glucose values declined within the first 24 h; however, animals remained
hyperglycemic (Fig. 7A). Hypothesizing that the level of immune protection may be related to the amount
of Oligomer (or fibril density), follow-up animals were performed using an Oligomer concentration of 4.2
mg/ml, which corresponds roughly to an Oligomer stiffness value of 2,000 Pa and polymerization half-time
of 16.30 ± 0.02 s. In this case, diabetes was reversed within 24 h with blood glucose values gradually
increasing above the diabetic threshold after ~40 days (Fig. 7A). Histopathologic and immunostaining
analyses of 60-day Oligomer-islet explants showed insulin- and glucagon-positive islets surrounded by
fibrillar Oligomer (Fig. 7, B–D). Interestingly, a subset of islets showed no evidence of a foreign body
response, while others showed very mild inflammatory infiltrate. In some instances, nearby vasculature was
evident (Fig. 7, E and F); however, vascularization and inflammation events did not appear to be correlated.
DISCUSSION
Previous attempts to restore islet-ECM interactions via micro- or macroencapsulation strategies have
yielded variable improvement in islet survival and function, with few studies focusing on the role of
material biophysical properties. In this study, we show Oligomer fibril architecture, and its capacity to be
precision tuned, is important when developing a macroencapsulation strategy for sustaining functional islet
masses in vitro and in vivo. Oligomer rapidly transitions from liquid to a solid scaffold, facilitating in situ
macroencapsulation not only within cultureware but also subcutaneously following simple injection
through small-bore needles (26 gauge). The higher-order suprafibrillar assembly and improved proteolytic
resistance imparted by natural intermolecular crosslinks present within Oligomer molecules (6) addressed a
number of shortcomings associated with previous collagen-encapsulation and subcutaneous transplantation
strategies.
Upon islet isolation and conventional culture in suspension, insulin-producing β cells undergo multiple cell
death processes including apoptosis, anoikis, and necrosis, which has been attributed to the loss of critical
cell-ECM interactions, biophysical cues, and vascularization (23, 44, 54, 70). While there is ample
evidence that entrapment of islets in conventional monomeric type I collagen enhances islet survival and
insulin secretory function in vitro (11, 24, 36, 43), these constructs are reported to be prone to contraction,
poor mechanical stability, and rapid degradation (21, 24). This has prompted the use of collagen in
combination with chemical crosslinking agents (21), nature-derived and synthetic copolymers (19, 21, 33,
40), and microfabricated scaffolds (13) to improve mechanical properties and resistance to proteolytic
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degradation. For example, Ghahary’s group (21) reported that treatment of fibroblast populated collagen
matrices with glutaraldehye crosslinking and polyvinyl alcohol (PVA)-borate networks yielded improved in
vitro islet viability and function compared with untreated controls. Alternatively, islets have been cultured
on the surface of collagen-containing decellularized tissues, such as intestinal submucosa (74), liver (75),
lung (1), and pancreas (28), which, for the most part, are processed to maintain their native architecture and
mechanical properties.
In this report, we show that isolated islets, like a variety of stromal cell populations, actively engage
Oligomer fibrils, in an attempt to establish tensional homeostasis and a favorable mechanical environment
for cell function (22). As fibril density and associated matrix stiffness increase, islet cells are less able to
induce traction-mediated matrix deformation and reorganization. It is noteworthy that Oligomer matrices
possess a higher stiffness-to-fibril density ratio and broader range of tunability compared with their
monomeric collagen counterparts (32), offering greater resistance to cellular traction forces. Decreasing
islet-induced matrix remodeling by fine tuning Oligomer stiffness improved islet survival and
cytoarchitecture over the 14-day culture period as well as sustained glucose-responsive β-cell function
comparable to freshly isolated islets. The fact that no disintegration or degradation of Oligomer-islet
constructs occurred in vitro can be attributed to native intermolecular crosslinks, which are known to
decrease collagen turnover in vivo (3). While the observed density-dependent phenotypic modulation was
likely mediated, in part by, integrin-mediated mechanotransduction pathways, more detailed studies are
necessary to elucidate relevant molecular players.
Present-day clinical islet transplantation involves infusion of isolated islets through the portal vein into the
liver where they become lodged. Although this procedure is minimally invasive, a number of alternative
sites have been evaluated recently (18, 50). Our in situ macroencapsulation strategy targeted the
subcutaneous space, an advocated site for clinical islet delivery since it provides adequate space for implant
accommodation, ease of access for transplant administration and removal (if necessary), and amenability
for posttransplantation monitoring (77). Although the subcutaneous space facilitates administration, major
challenges for islet transplantation include poor oxygen tension and inadequate vascularization (60). In
fact, islet transplantation, whether alone or encapsulated, into an unmodified subcutaneous site has never
reversed diabetes in animals or humans as the microenvironment has been deemed inhospitable to cell
survival (46). It has been suggested that stimulation of angiogenesis is critical to successful subcutaneous
islet transplantation (47, 51, 55, 68), prompting investigation of a number of vascularization strategies.
Specifically, vascularization using empty devices or other synthetic materials pretransplantation of islets
(16, 35, 45, 46, 61, 62), oxygen generators (37, 38), and cotransplantation of soluble factors (e.g., fibroblast
growth factor, hepatocyte growth factor, and vascular endothelial growth factor) (29, 71) or cells (e.g.,
fibroblasts, mesenchymal stem cells, and endothelial cells) (48, 49, 71) have all been explored with
variable success. For most of these strategies, there is a 1- to 4-wk posttransplantation delay for animals to
achieve normoglycemia as islet health and site vascularization and mass transport properties presumably
become sufficient for normal glucose homeostasis.
Our approach, which involved subcutaneous injection and in situ Oligomer-islet macroencapsulation,
resulted in rapid lowering, within 24 h, of blood glucose values below the diabetic threshold with
histological evidence of functional vascularization within 14 days. This uncommon rapid recovery of
normoglycemia was observed in immunocompromised, syngeneic, and allogeneic models, suggesting that
the natural and stable fibrillar scaffold formed Oligomer acted to sustain the glucose-sensitive insulin
secreting function of islets as well as support the necessary molecular diffusion and transport. The mass
transport properties of Oligomer, and their dependence on fibril density and molecular size, have been
previously defined experimentally and computationally (72). Following injection and throughout the study
duration, Oligomer-islet constructs remained identifiable, facilitating retrievability from their subcutaneous
locations. Oligomer material persisted, appearing as normal collagenous connective tissue with density-
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dependent fibroblast infiltration and no evidence of inflammatory or foreign body response, which is
consistent with previous reports where Oligomer has been implanted in other anatomical locations (8, 76).
Clearly, the stability and persistence of Oligomer was critical to prolonged islet survival and function, with
multiple groups previously attributing failure of collagen-encapsulated islet transplantation to rapid in vivo
degradation (15, 21, 69). Also, the volume ratio of fibrillar Oligomer to islets was critical to uniform
encapsulation and consistent maintenance of a functional β cell mass, with the highest fibril densities
required for allogeneic islet transplants. In the present study, Oligomer contributed to an engraftment
response marked by “tissue integration” rather than a fibrotic, foreign-body reaction, which is known to be
detrimental to islet health and glucose-insulin transport (2, 46). These results were encouraging since
alginate, as well as other nature-derived and synthetic materials, have a long history of biocompatibility
issues leading to early graft failure due to fibrosis (9, 57, 67). To the best of our knowledge, this is the first
report of successful subcutaneous islet transplantation with rapid lowering of blood glucose using an
injectable in situ Oligomer-islet macroencapsulation strategy.
In conclusion, Oligomer fibril architecture was an important determinant of viability, morphology, and
function of transplanted islets as well as islets cultured in vitro. While the exact mechanisms underlying the
observed improvement in islet function have yet to be determined, we suppose that the ability of oligomers
to recreate fibrillar collagen in its natural and stable format contributes in a multifaceted fashion. More
specifically, its high in vivo biocompatibility, with no inflammatory reaction, likely contributes to improved
islet health and β cell mass engraftment. The fact that increased survival and function of macroencapsulated
islets was observed both in vitro and in vivo suggests that physical support provided by the scaffold,
together with receptor-mediated (e.g., integrin) engagement, assists in maintaining essential survival and
differentiation signaling pathways. The integration of the oligomer scaffold within the subcutaneous space
and associated vascularization supports essential oxygen diffusion and molecular transport while reducing
inflammatory cell infiltrate and activation, even in the presence of allograft islets. Additional studies are
currently under way to further validate and optimize islet subcutaneous delivery as well as define islet
dose-response. The ability of Oligomer to provide important microenvironmental cues that positively
impact islet survival while overcoming major shortcomings of conventional encapsulation strategies
positions it well as a tool for 1) in vitro maintenance of islet viability and function following isolation as
well as 2) the design of functional subcutaneous islet transplant solutions.
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Fig. 1.
Open in a separate window
Islets macroencapsulated in Oligomer show sustained viability and fibril density-dependent traction forces following 14
days of in vitro culture. Representative images of calcein AM (green)- and PI (red)-stained islets after 14 days of culture in
suspension (A), macroencapsulated in Oligomer-1.5 (B), or macroencapsulated in Oligomer-3.0 (C). Confocal reflection
images show islet-induced collagen-fibril deformation (arrows) within Oligomer-1.5 (D) but not Oligomer-3.0 (E). Scale
bar = 50 µm (A–C) and 100 µm (D and E).
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Fig. 2.
Open in a separate window
Islets macroencapsulated in Oligomer maintain morphology and function following 14 days of in vitro culture. A:
immunostaining shows islet cytoarchitecture with insulin- (green) and glucagon-positive (purple) cells within
Oligomer-1.5 and Oligomer-3.0. Islet cell nuclei (blue) were visualized with DRAQ5. Scale bar = 30 µm. B: 14-day
normalized stimulation indexes (means ± SD; n = 8–12) as measured by glucose-stimulated insulin release. Values were
normalized to stimulation indexes for freshly isolated (day 0) islets. *Mean SI value for 14-day suspension islets was
significantly less than the value for freshly isolated islets (P < 0.05).
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Fig. 3.
Open in a separate window
A: schematic summarizing in situ subcutaneous Oligomer-islet macroencapsulation within diabetic recipients. Islets were
isolated from normal donor mice, suspended within neutralized Oligomer solutions, and injected subcutaneously into two
dorsal sites within streptozotocin-induced diabetic mice. Immediately upon injection, the Oligomer-islet suspension self-
assembled, transitioning from a liquid to a solid collagen-fibril scaffold and entrapping islets. B: nonfasting blood glucose
levels (means ± SD) following subcutaneous macroencapsulation of C57BL/6J islets in various Oligomer formulations (n
= 3 for each formulation) into diabetic NOD.SCID mice compared with subcutaneous injection of islets only (n = 4) and
Oligomer only (n = 3) control groups.
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Fig. 4.
Histopathological and immunohistochemical analysis of C57BL/6J islet explants in 1.5 mg/ml (A–D), 2.2 mg/ml (E–H), 3
mg/ml (I–L), and saline (M–O) 14 days following subcutaneous transplantation in diabetic immunocompromised
NOD.SCID mice. Oligomer-islet constructs were readily identifiable between the panniculus carnosus muscle (PCM) and
the skeletal muscle facial layers (SMF). Masson’s trichrome-stained sections (A, E, I) showed an increase in the amount of
fibrillar collagen and more uniform islet encapsulation as Oligomer concentration was increased. Islets maintained
multicellular cytoarchitecture with cells staining positively for insulin (green) and glucagon (purple) (D, H, L, O). Cell
nuclei were stained with DAPI. H&E-stained sections indicated functional vascularization of islets and no evidence of
Oligomer degradation, inflammation, or foreign body response. In contrast, injection of islets only resulted in formation of
a large granuloma with loss of normal multicellular morphology and protein expression (M–O).
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Fig. 5.
Open in a separate window
A: nonfasting blood glucose levels (means ± SD) following subcutaneous in situ macroencapsulation of syngeneic islets in
Oligomer (3 mg/ml; n = 3) within diabetic C57BL/6J mice compared with islet only group (n = 3). Mice receiving
macroencapsulated islets achieved normoglycemia within 24 h following transplantation. Blood glucose remained below
the diabetic threshold (<250 mg/dl) throughout the 90-day study period. The control group remained diabetic throughout
the study with widely varying blood glucose values. B–E: GTT (mean ± SD) and associated AUC (mean ± SD) analysis 15
(B, C) and 90 (D, E) days following transplantation demonstrated the capacity of islets + Oligomer group but not islets-
only group to rapidly regulate blood glucose levels following glucose injection. AUC values for islets + Oligomer group
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were significantly (P < 0.05) less than those for islet only controls at both time points.
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Fig. 6.
Histopathological analysis of Oligomer-encapsulated (3 mg/ml), syngeneic islets 90 days following subcutaneous
transplantation within diabetic mice. A, B: H&E-stained cross-section showing Oligomer encapsulated islets within the
subcutaneous space below the panniculus carnosus muscle (PCM). The self-assembled Oligomer matrix persisted and
integrated with surrounding host tissues, with evidence of functional revascularization. C: encapsulated islets stained
positive for insulin (green) and glucagon (purple). D, E: CD31 (purple) staining confirmed the presence of endothelial
cells near islets costained to visualize insulin (green) and nuclei (blue). F, G: histopathological analysis of explant 90 days
following subcutaneous transplantation of islets only within diabetic mice showed evidence of inflammatory-mediated
destruction and necrosis of islets.
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Fig. 7.
A: nonfasting blood glucose levels (means ± SD) following subcutaneous in situ macroencapsulation of allogeneic CD1
mouse islets in Oligomer concentrations of 3.0 mg/ml (n = 3) and 4.2 mg/ml (n = 5) within diabetic C57BL/6J mice. B–F:
histopathological analysis of Oligomer-encapsulated (4.2 mg/ml), allogeneic islets 60 days following subcutaneous
transplantation. B, C: H&E-stained cross-sections showing encapsulated islets within the subcutaneous space below the
panniculus carnosus muscle. D: islets stained positive for insulin (green) and glucagon (purple). E, F: CD31 (purple)
staining confirmed the presence of endothelial cells near islets costained for insulin (green) and nuclei (blue).
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